936727-05-8

For more than ten years, we have been committed to custom synthesis and mass production of compounds. If you are looking for a supplier or manufacturer of Lumacaftor (CAS:936727-05-8), please contact us. We can provide customers with high-quality compounds and good service. Now, we also hope to meet your needs for Lumacaftor (CAS: 936727-05-8) and other compounds.

Send Inquiry

Product Description

Name	Lumacaftor
Synonyms	VX-809 (Lumacaftor);3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid;3-(6-{[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoic acid;VX-809;3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid
Molecular Formula	C₂₄H₁₈F₂N₂O₅
Molecular Weight	452.40700
CAS Number	936727-05-8
purity	≥98%
Storage conditions	Inert atmosphere,2-8°C

Applications：

Lumacaftor (VX-809) (CAS:936727-05-8) is a pharmaceutical drug that acts as a chaperone during protein folding and increases the number of CFTR proteins that are trafficked to the cell surface. It is available in a single pill with ivacaftor; the combination, lumacaftor/ivacaftor (brand name Orkambi), is used to treat people with cystic fibrosis who have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease. It was developed by Vertex Pharmaceuticals and the combination was approved by the FDA in 2015. As of 2015 lumacaftor had no medical use on its own.

Hot Tags: